Literature DB >> 20556443

Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease.

Zhanyun Lv1, Hong Jiang, Huamin Xu, Ning Song, Junxia Xie.   

Abstract

The staging of Lewy-related pathology in sporadic Parkinson's disease (PD) reveals that many brain nuclei are affected in PD during different stages, except the ventral tegmental area (VTA), which is close related to the substantia nigra (SN) and enriched in dopamine (DA) neurons. Why DA neurons are selectively degenerated in the SN of PD is far from known. In the present study, we observed that the number of tyrosine hydroxylase immunoreactive neurons decreased and iron-staining positive cells increased in the SN, but not in the VTA, in the chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated PD mice. Increased expression of divalent metal transporter 1 and decreased expression of ferroportin 1 might associate with this increased nigral iron levels. Lipofuscin granular aggregations and upregulation of alpha-synuclein (α-synuclein) were also observed only in the SN. These results suggest that increased iron levels associate with the selective degeneration of DA neurons in the SN. The intracellular regulation mechanisms for the iron transporters may be different in the SN and VTA under the same conditions. Moreover, the lipofuscin granular aggregations and upregulation of α-synuclein were also involved in the selective degeneration of dopaminergic neurons in the SN.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20556443     DOI: 10.1007/s00702-010-0434-3

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  48 in total

1.  The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.

Authors:  N Ostrerova-Golts; L Petrucelli; J Hardy; J M Lee; M Farer; B Wolozin
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

2.  Metal-catalyzed oxidation of alpha-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments.

Authors:  Nelson B Cole; Diane D Murphy; Jacob Lebowitz; Luca Di Noto; Rodney L Levine; Robert L Nussbaum
Journal:  J Biol Chem       Date:  2004-12-21       Impact factor: 5.157

3.  Treatment with nerve growth factor decreases expression of divalent metal transporter 1 and transferrin receptor in PC12 cells.

Authors:  Jun Wang; Zhong-ming Qian; Hong Jiang; Junxia Xie; Ya Ke
Journal:  Neurochem Int       Date:  2005-12       Impact factor: 3.921

4.  Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys.

Authors:  H Mochizuki; H Imai; K Endo; K Yokomizo; Y Murata; N Hattori; Y Mizuno
Journal:  Neurosci Lett       Date:  1994-02-28       Impact factor: 3.046

5.  Relationship of substantia nigra echogenicity and motor function in elderly subjects.

Authors:  D Berg; C Siefker; P Ruprecht-Dörfler; G Becker
Journal:  Neurology       Date:  2001-01-09       Impact factor: 9.910

6.  Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein.

Authors:  Natalie Golts; Heather Snyder; Mark Frasier; Catherine Theisler; Peter Choi; Benjamin Wolozin
Journal:  J Biol Chem       Date:  2002-02-15       Impact factor: 5.157

7.  Divalent metal transporter 1 up-regulation is involved in the 6-hydroxydopamine-induced ferrous iron influx.

Authors:  Ning Song; Hong Jiang; Jun Wang; Jun-Xia Xie
Journal:  J Neurosci Res       Date:  2007-11-01       Impact factor: 4.164

8.  Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells.

Authors:  Shuzhen Zhang; Jun Wang; Ning Song; Junxia Xie; Hong Jiang
Journal:  Neurobiol Aging       Date:  2008-01-08       Impact factor: 4.673

9.  An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.

Authors:  C M Waters; S P Hunt; P Jenner; C D Marsden
Journal:  Neuroscience       Date:  1987-12       Impact factor: 3.590

10.  Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers.

Authors:  Marcus Kostka; Tobias Högen; Karin M Danzer; Johannes Levin; Matthias Habeck; Andreas Wirth; Richard Wagner; Charles G Glabe; Sabine Finger; Udo Heinzelmann; Patrick Garidel; Wenzhen Duan; Christopher A Ross; Hans Kretzschmar; Armin Giese
Journal:  J Biol Chem       Date:  2008-02-07       Impact factor: 5.157

View more
  21 in total

1.  Longitudinal Development of Brain Iron Is Linked to Cognition in Youth.

Authors:  Bart Larsen; Josiane Bourque; Tyler M Moore; Azeez Adebimpe; Monica E Calkins; Mark A Elliott; Ruben C Gur; Raquel E Gur; Paul J Moberg; David R Roalf; Kosha Ruparel; Bruce I Turetsky; Simon N Vandekar; Daniel H Wolf; Russell T Shinohara; Theodore D Satterthwaite
Journal:  J Neurosci       Date:  2020-01-27       Impact factor: 6.167

2.  Low Levels of Prohibitin in Substantia Nigra Makes Dopaminergic Neurons Vulnerable in Parkinson's Disease.

Authors:  Debashis Dutta; Nilufar Ali; Emili Banerjee; Raghavendra Singh; Amit Naskar; Ramesh Kumar Paidi; Kochupurackal P Mohanakumar
Journal:  Mol Neurobiol       Date:  2017-01-06       Impact factor: 5.590

3.  Ironing out neurodegeneration: iron chelation for neuroprotection.

Authors:  Joshua L Dunaief
Journal:  Free Radic Biol Med       Date:  2011-05-14       Impact factor: 7.376

4.  Neuroprotective Effects of Intranasal IGF-1 against Neonatal Lipopolysaccharide-Induced Neurobehavioral Deficits and Neuronal Inflammation in the Substantia Nigra and Locus Coeruleus of Juvenile Rats.

Authors:  Lu-Tai Tien; Yih-Jing Lee; Yi Pang; Silu Lu; Jonathan W Lee; Chih-Hsueh Tseng; Abhay J Bhatt; Renate D Savich; Lir-Wan Fan
Journal:  Dev Neurosci       Date:  2017-08-05       Impact factor: 2.984

5.  Epigallocatechin Gallate Has a Neurorescue Effect in a Mouse Model of Parkinson Disease.

Authors:  Qi Xu; Monica Langley; Anumantha G Kanthasamy; Manju B Reddy
Journal:  J Nutr       Date:  2017-08-23       Impact factor: 4.798

Review 6.  Lysosomal dysfunction in neurodegeneration: emerging concepts and methods.

Authors:  Vinod Udayar; Yu Chen; Ellen Sidransky; Ravi Jagasia
Journal:  Trends Neurosci       Date:  2022-01-13       Impact factor: 13.837

7.  Overdosing on iron: Elevated iron and degenerative brain disorders.

Authors:  Santosh R D'Mello; Mark C Kindy
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-02

Review 8.  Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities.

Authors:  Neena Singh; Swati Haldar; Ajai K Tripathi; Katharine Horback; Joseph Wong; Deepak Sharma; Amber Beserra; Srinivas Suda; Charumathi Anbalagan; Som Dev; Chinmay K Mukhopadhyay; Ajay Singh
Journal:  Antioxid Redox Signal       Date:  2013-08-15       Impact factor: 8.401

9.  Oral administration of the iron chelator deferiprone protects against loss of retinal ganglion cells in a mouse model of glaucoma.

Authors:  Qi N Cui; Albert R Bargoud; Ahmara G Ross; Ying Song; Joshua L Dunaief
Journal:  Exp Eye Res       Date:  2020-02-08       Impact factor: 3.467

10.  Role and mechanism of microglial activation in iron-induced selective and progressive dopaminergic neurodegeneration.

Authors:  Wei Zhang; Zhao-fen Yan; Jun-hua Gao; Li Sun; Xi-yan Huang; Zhuo Liu; Shu-yang Yu; Chen-Jie Cao; Li-jun Zuo; Ze-Jie Chen; Yang Hu; Fang Wang; Jau-shyong Hong; Xiao-min Wang
Journal:  Mol Neurobiol       Date:  2013-11-26       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.